Tempus AI (NASDAQ:TEM) Stock Gets Price Target Bump from JPMorgan Chase & Co.

Tempus AI (NASDAQ:TEM) had its price target hoisted by investment analysts at JPMorgan Chase & Co. from $45.00 to $70.00 in a report released on Wednesday, Benzinga reports. The firm presently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s target price suggests a potential upside of 2.46% from the company’s previous close.

TEM has been the subject of a number of other reports. Needham & Company LLC restated a “buy” rating and issued a $75.00 target price on shares of Tempus AI in a research note on Friday, July 31st. TD Cowen reissued a “buy” rating on shares of Tempus AI in a research report on Wednesday, July 15th. Lake Street Capital lowered shares of Tempus AI to a “hold” rating in a research report on Monday, July 20th. Freedom Capital upgraded Tempus AI to a “hold” rating in a research note on Tuesday, June 30th. Finally, HC Wainwright boosted their price target on Tempus AI from $56.00 to $66.00 and gave the company a “buy” rating in a research note on Friday, September 11th. Eleven research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $72.37.

Tempus AI Stock Performance

Shares of NASDAQ TEM traded up $0.10 during mid-day trading on Wednesday, hitting $68.32. The company had a trading volume of 6,007,028 shares, compared to its average volume of 6,222,563. Tempus AI has a 12 month low of $40.77 and a 12 month high of $97.25. The firm has a market cap of $12.33 billion, a P/E ratio of -47.44 and a beta of 3.54. The business’s 50-day simple moving average is $66.88 and its 200-day simple moving average is $56.07. The company has a debt-to-equity ratio of 3.06, a current ratio of 3.30 and a quick ratio of 3.16.

Tempus AI (NASDAQ:TEM) last issued its quarterly earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.10. The firm had revenue of $382.49 million for the quarter, compared to analyst estimates of $379.69 million. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%. The company’s quarterly revenue was up 21.6% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.22) earnings per share. As a group, analysts predict that Tempus AI will post -1.38 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Tempus AI news, CFO James Rogers sold 26,313 shares of the business’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $60.00, for a total value of $1,578,780.00. Following the transaction, the chief financial officer owned 106,024 shares of the company’s stock, valued at approximately $6,361,440. The trade was a 19.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Andrew Polovin sold 22,148 shares of the firm’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $49.61, for a total value of $1,098,762.28. Following the completion of the sale, the executive vice president owned 146,067 shares of the company’s stock, valued at approximately $7,246,383.87. This trade represents a 13.17% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 1,280,965 shares of company stock worth $80,397,564. 24.26% of the stock is owned by company insiders.

Institutional Investors Weigh In On Tempus AI

Institutional investors and hedge funds have recently made changes to their positions in the company. Ulland Investment Advisors LLC acquired a new position in shares of Tempus AI during the third quarter valued at $41,000. Fagan Associates Inc. bought a new position in Tempus AI in the third quarter valued at about $5,265,000. GK Wealth Management LLC bought a new position in Tempus AI in the third quarter valued at about $91,000. Post Resch Tallon Group Inc. acquired a new stake in Tempus AI in the third quarter worth about $532,000. Finally, GAMMA Investing LLC increased its position in Tempus AI by 54.3% in the third quarter. GAMMA Investing LLC now owns 1,239 shares of the company’s stock worth $101,000 after purchasing an additional 436 shares during the period. Institutional investors own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus AI, Inc is a technology company focused on applying artificial intelligence and data analytics to precision medicine. The company develops tools intended to help physicians make more informed treatment decisions by combining clinical information, molecular data and other health-related datasets.

Tempus provides genomic testing and diagnostic services, including sequencing and other molecular tests used primarily in oncology. Its platform also offers data and software solutions designed to support clinical research, pharmaceutical development, patient identification for clinical trials and the development of personalized treatment strategies.

Founded in 2015, Tempus is headquartered in Chicago and primarily serves healthcare providers, researchers and life sciences companies.